Xeris Pharmaceuticals (XERS) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98422E1038
Xeris Pharmaceuticals Inc. is a biopharmaceutical company based in Illinois that focuses on developing and selling innovative therapies. One of their notable products is Gvoke, a liquid-stable glucagon used to treat severe hypoglycemia. In addition, they offer Keveyis, a therapy for various paralysis types, and Recorlev, an inhibitor targeted at Cushing's syndrome. The company's commitment to advancements is reflected in their ongoing development programs and proprietary formulation technologies - XeriSol and XeriJect.
Since its establishment in 2005, Xeris Pharmaceuticals has been dedicated to improving patient care and expanding treatment options. Located in Chicago, Illinois, the company continues to strive for excellence and innovation in the pharmaceutical industry. To learn more about Xeris Pharmaceuticals and their products, visit their official website: https://www.xerispharma.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
XERS Stock Overview
| Market Cap in USD | 285m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 2018-06-21 |
XERS Stock Ratings
| Growth 5y | -4.98 |
| Fundamental | -47.4 |
| Dividend | - |
| Rel. Performance vs Sector | -3.02 |
| Analysts | 4.67/5 |
| Fair Price Momentum | 1.37 USD |
| Fair Price DCF | - |
XERS Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
XERS Growth Ratios
| Growth 12m | -19.46% |
| Growth Correlation 12m | -19% |
| Growth Correlation 3m | -61% |
| CAGR 5y | -29.08% |
| Sharpe Ratio 12m | -0.34 |
| Alpha vs SP500 12m | -61.52 |
| Beta vs SP500 5y weekly | 1.75 |
| ValueRay RSI | 17.92 |
| Volatility GJR Garch 1y | 77.09% |
| Price / SMA 50 | -25.52% |
| Price / SMA 200 | -19.46% |
| Current Volume | 1339.8k |
| Average Volume 20d | 1491.2k |
External Links for XERS Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 24, 2024, the stock is trading at USD 1.78 with a total of 1,339,837 shares traded.
Over the past week, the price has changed by -1.11%, over one month by -15.24%, over three months by -26.75% and over the past year by -22.27%.
According to ValueRays Forecast Model, XERS Xeris Pharmaceuticals will be worth about 1.5 in April 2025. The stock is currently trading at 1.78. This means that the stock has a potential downside of -14.04%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 4.8 | 167 |
| Analysts Target Price | 4.9 | 175 |
| ValueRay Target Price | 1.5 | -14.0 |